GTx, Inc. (Nasdaq: GTXI) announced today that a poster presentation, entitled Results from two Phase 3 randomized trials of enobosarm, a selective androgen receptor modulator (SARM), for the prevention and treatment of muscle wasting in patients with non-small cell lung cancer (NSCLC) receiving chemotherapy, will be given by Jeffrey Crawford, M.D., Chief, Division of Medical Oncology at Duke University School of Medicine, and principal investigator for the POWER1 (platinum plus taxane) and POWER2 (platinum plus non-taxane) trials, which were chemotherapy add-on placebo controlled studies.
Help employers find you! Check out all the jobs and post your resume.
